HC Wainwright Has Negative Outlook for BCRX Q3 Earnings

Key Points

• HC Wainwright has reduced the Q3 2025 earnings estimate for BioCryst Pharmaceuticals (BCRX) from $0.13 to $0.02 per share.
• The current consensus estimate for BioCryst Pharmaceuticals' full-year earnings is (0.36) per share, highlighting ongoing financial challenges.
• Despite the negative outlook, HC Wainwright maintains a "Buy" rating for BCRX with a target price of $30.00.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at HC Wainwright decreased their Q3 2025 EPS estimates for shares of BioCryst Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 5th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.02 per share for the quarter, down from their prior estimate of $0.13. HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals' Q4 2025 earnings at $0.03 EPS, FY2025 earnings at $0.07 EPS, FY2026 earnings at $0.31 EPS, FY2027 earnings at $0.71 EPS, FY2028 earnings at $1.24 EPS and FY2029 earnings at $1.87 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. BioCryst Pharmaceuticals's revenue for the quarter was up 49.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.06) earnings per share.

Several other equities analysts also recently issued reports on BCRX. Wedbush boosted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. Royal Bank Of Canada restated an "outperform" rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. JPMorgan Chase & Co. lifted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Finally, Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Trading Down 2.5%

BioCryst Pharmaceuticals stock traded down $0.21 during mid-day trading on Thursday, reaching $8.10. The company's stock had a trading volume of 1,049,731 shares, compared to its average volume of 3,871,523. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -44.97, a PEG ratio of 1.89 and a beta of 1.10. The business has a 50 day moving average price of $9.32 and a 200-day moving average price of $8.77. BioCryst Pharmaceuticals has a twelve month low of $6.01 and a twelve month high of $11.31.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. bought a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $80,000. Sei Investments Co. raised its holdings in BioCryst Pharmaceuticals by 2.8% in the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock valued at $430,000 after acquiring an additional 1,537 shares in the last quarter. Norges Bank acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth $3,947,000. Pictet Asset Management Holding SA raised its holdings in shares of BioCryst Pharmaceuticals by 34.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 26,442 shares of the biotechnology company's stock worth $199,000 after buying an additional 6,840 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in BioCryst Pharmaceuticals by 53.2% during the 4th quarter. Wells Fargo & Company MN now owns 104,163 shares of the biotechnology company's stock worth $783,000 after acquiring an additional 36,166 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.